MENU
EOLS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

EOLS stock forecast, quote, news & analysis

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market... Show more

EOLS
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for EOLS with price predictions
Sep 11, 2026

Aroon Indicator for EOLS shows an upward move is likely

EOLS's Aroon Indicator triggered a bullish signal on September 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 216 similar instances where the Aroon Indicator showed a similar pattern. In 194 of the 216 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

EOLS moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EOLS crossed bullishly above the 50-day moving average on August 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +6.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where EOLS advanced for three days, in 204 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

EOLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for EOLS moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 19 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.

The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EOLS as a result. In 73 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for EOLS turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 33 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EOLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. EOLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (114.943) is normal, around the industry mean (46.728). P/E Ratio (0.000) is within average values for comparable stocks, (93.360). EOLS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.931). EOLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.613) is also within normal values, averaging (176.516).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EOLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -5%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 30%. SXTC experienced the highest price growth at 15%, while GELS experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was -4% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
EOLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of neurotoxins

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Major
Address
520 Newport Center Drive
Phone
+1 949 284-4555
Employees
334
Web
https://www.evolus.com
Aroon Indicator for EOLS shows an upward move is likely